Tissue specific prognostic impact of TP53 and BRCA1 and BRCA2 mutations in breast and ovarian cancers using TCGA data
Discover Medicine · 17.04.2026 · 3 (1)
DOI: 10.1007/s44337-026-00599-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Medicine, online erschienen am 17.04.2026. Verfasst von Parvin Pourmasoumi. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although mutations in TP53 and BRCA1/2 are central to the biology of breast and ovarian cancers, their prognostic roles remain debated, with little attention to tissue-specific differences. Understanding whether the same mutation carries opposite survival implications across cancer types could reshape biomarker interpretation.
Methods
We interrogated TCGA cohorts of breast cancer ( n = 967) and ovarian cancer (OV; n = 571), defining mutation status by non-synonymous variants. Overall survival was assessed using Kaplan–Meier and multivariable Cox regression models, adjusted for clinical covariates. Complete-case subsets were analyzed for robustness.
Results
In breast cancer, BRCA2 mutations conferred a strikingly adverse prognosis (HR = 3.91; 95% CI, 1.10–13.9; p = 0.034), while BRCA1 and TP53 showed no clear effects. By contrast, in OV, BRCA2 mutations were linked to markedly improved survival (HR = 0.18; 95% CI, 0.04–0.82; p = 0.018). BRCA1 showed a trend toward benefit, whereas TP53 mutations, though nearly ubiquitous, were not prognostic.
Conclusions
This work uncovers a paradoxical, tissue-specific divergence in the prognostic value of BRCA2 mutations: detrimental in breast cancer yet favorable in OV. Such opposing effects have not been systematically highlighted before and emphasize the need for cancer-type–tailored biomarker strategies. These results are hypothesis-generating but highlight the translational importance of context in precision oncology.
Zitieren
APA
Pourmasoumi, P. (2026). Tissue specific prognostic impact of TP53 and BRCA1 and BRCA2 mutations in breast and ovarian cancers using TCGA data. Discover Medicine, 3(1). https://doi.org/10.1007/s44337-026-00599-4
Vancouver
Pourmasoumi P. Tissue specific prognostic impact of TP53 and BRCA1 and BRCA2 mutations in breast and ovarian cancers using TCGA data. Discover Medicine. 2026;3(1). doi:10.1007/s44337-026-00599-4
BibTeX
@article{Pourmasoumi2026,
author = {Pourmasoumi, Parvin},
title = {Tissue specific prognostic impact of TP53 and BRCA1 and BRCA2 mutations in breast and ovarian cancers using TCGA data},
journal = {Discover Medicine},
year = {2026},
volume = {3},
number = {1},
doi = {10.1007/s44337-026-00599-4}
}
EUVIMED